Calendar
February 28 – March 1
March 12 – 14
April 18 – 22
2015 Highlights of ASH® in Asia
National Comprehensive Cancer Network’s
20th Annual Conference
2015 American Association for Cancer
Research Annual Meeting
Bangkok, Thailand
Hollywood, FL
The NCCN 20th Annual Conference will gather more than
1,500 oncology professionals to discuss the latest cancer
therapies and advancing the standard of cancer care.
April 23 – 24
2015 Highlights of ASH® in Latin America
Cartagena, Colombia
Hear internationally recognized experts analyze the
latest updates in hematology research from the ASH
Annual meeting.
Philadelphia, PA
The AACR Annual Meeting 2015 will highlight the latest
discoveries in every area of cancer research. This year’s
meeting theme is “Bringing Cancer Discoveries to
Patients.”
Cartagena, Colombia
BRIEF SUMMARY: For Full Prescribing Information, see package insert.
CONTRAINDICATIONS None.
WARNINGS AND PRECAUTIONS Thrombocytopenia, Anemia and Neutropenia Treatment with
Jakafi can cause thrombocytopenia, anemia and neutropenia. [see Dosage and Administration (2.1) in Full
Prescribing Information]. Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi.
Platelet transfusions may be necessary [see Dosage and Administration (2.1.1) and Adverse Reactions (6.1) in Full
Prescribing Information]. Patients developing anemia may require blood transfusions and/or dose modifications of
Jakafi. Severe neutropenia (ANC less than 0.5 X 109/L) was generally reversible by withholding Jakafi until
recovery [see Adverse Reactions (6.1)]. Perform a pre-treatment complete blood count (CBC) and monitor CBCs
every 2 to 4 weeks until doses are stabilized, and then as clinically indicated. [see Dosage and Administration
(2.1.1) and Adverse Reactions (6.1) in Full Prescribing Information]. Risk of Infection Serious bacterial,
mycobacterial, fungal and viral infections have occurred. Delay starting therapy with Jakafi until active serious
infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage
promptly. Tuberculosis Tuberculosis in fV7F